CA
DMAC icon

Corriente Advisors’s DiaMedica Therapeutics DMAC Stock Holding History

Corriente Advisors’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-203,641
Closed -$906K – 12
2021
Q2 		$906K Sell
203,641
-666,587
-77% -$5.47M 0.49% 15
2021
Q1 		$7.96M Buy
870,228
+63,328
+8% +$592K 2.93% 9
2020
Q4 		$8.18M Buy
806,900
+76,900
+11% +$421K 1.95% 14
2020
Q3 		$3.1M Buy
730,000
+528,752
+263% +$2.8M 1.57% 14
2020
Q2 		$1.4M Buy
+201,248
New +$898K 0.9% 12

Other funds holding DMAC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
JAMONY
Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return
MHP
Manatuck Hill Partners Westport, Connecticut $370M AUM 95.53% 1-Year Est. Return
CLG
Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Corriente Advisors's DMAC Position: Q3 2021 in Review

Corriente Advisors sold out of DiaMedica Therapeutics (DMAC) in Q3 2021, closing a stake of 203,641 shares — an estimated $906K sold.

Corriente Advisors first reported a position in DMAC in Q2 2020 and held it in 5 quarters. The position peaked at $8.18M in Q4 2020. 34 funds tracked by Wall St. Rank hold DMAC as of Q3 2021.

  • Corriente Advisors reported no remaining DiaMedica Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Corriente Advisors sold 203,641 DiaMedica Therapeutics shares in Q3 2021, an estimated $906K.
  • Corriente Advisors first reported a position in DiaMedica Therapeutics in Q2 2020 and held it in 5 quarters.
  • Corriente Advisors's DiaMedica Therapeutics position peaked at $8.18M in Q4 2020.
  • 34 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q3 2021.

Based on Corriente Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.